Ionis Pharmaceuticals Inc. (NASDAQ:IONS) changes shares on Friday trading session, with a change of 3.29% or $1.86 shares. The trading starts at $57.61 and closed at $56.51 throughout the day. The trading session low price was $56.63 and day high was $58.50 on Friday, June 12. After the session, the Healthcare sector daily volume shifted to 1.01 million while its average volume is 924.98K. In other hand, the IONS market cap reached to $7.87B. While, its current target price is $58.37 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 1.41% and up 7.24% for month. Its quarterly performance was 20.57% above, while its half year performance is down -5.38%. IONS yearly performance stood at negative -8.63% and fall -3.38% for year-to-date. Current recommendation for Ionis Pharmaceuticals Inc. is 2.60.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. IONS EPS (TTM) for 12-month is 1.12. EPS for this year is 572.90%, while for the next year its value is -0.17. Sales growth for the current quarter is 1.06 while its EPS Q/Q reached -158.00%. It has an EPS of 52.40% up for past five years and for the next five years will be up 49.00%.
FMR, LLC, Vanguard Group, Inc. (The) and Baillie Gifford and Company are the top three holders in Ionis Pharmaceuticals Inc. (IONS) stock. On Mar 30, 2020, FMR, LLC has 20.96 million shares which valued 991.0 million. On Mar 30, 2020, Vanguard Group, Inc. (The) owned 12.05 million shares which valued at 569.89 million. On Mar 30, 2020, Baillie Gifford and Company has a total of 8.75 million shares which valued at 413.5 million. In the end, Baillie Gifford and Company have 6.28% shares outstanding of Ionis Pharmaceuticals Inc. (IONS) on Mar 30, 2020. The insider ownership moved to 0.20% and institutional holding shifted to 87.10%.
The company posted an EPS (TTM) of 1.12. According to the most recent quarter report on (Jun 2020), 19 analysts estimated an average EPS of -0.22, while -0.01 EPS posted a year ago period. Analyst Estimated EPS for IONS published in the report was -0.4-0.05 during the same period. Comparing with last year, the average estimated EPS was -0.01 which is higher than -0.35 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for IONS rise 1.35% for period of 200 days. SMA for 50 days was 6.46% which is showing green signal, while SMA-20 was 4.34%. The moving average value for Ionis Pharmaceuticals Inc. (IONS) is 56.56 and 56.08 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in IONS stock. On Mar 25, CROOKE STANLEY T, Exec Chairman of the Board, sold 1,000 trading shares at the cost of $47.00, which valued at 47000.0. On Mar 25, CROOKE STANLEY T, Exec Chairman of the Board, sold 15,000 shares at the cost of $47.00, with total shares of 41,935. On Mar 19, CROOKE STANLEY T, Exec Chairman of the Board, sold 1,000 shares at the cost of 45.00. After this transaction, CROOKE STANLEY T total shares reached to 6,581 which valued at 45000.0.